单位：[1]Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[2]Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[3]Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[4]Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, China[5]Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China[6]Information Center, China-Japan Friendship Hospital, Beijing, China[7]Department of Clinical Laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells and does not have sufficient prognostic indicators. Interferon gamma inducible protein 16 (IFI16) plays a crucial role in B-cell differentiation. Several studies have shown that IFI16 predicted prognosis in many cancers. However, the relationship between MM prognosis and IFI16 expression has not been studied. In our study, we analyzed the prognostic role of IFI16 expression and explored the possible mechanism in MM progression by using 4498 myeloma patients and 52 healthy donors from 13 independent gene expression omnibus (GEO) datasets. The IFI16 expression increased with myeloma progression, ISS stage, 1q21 amplification, and relapse (all P < 0.01). MM patients with higher IFI16 expression had shorter survival in six datasets (all P < 0.05). Furthermore, multivariate analysis indicated that enhanced IFI16 expression was an independent poor prognostic factor for EFS and OS (P = 0.007, 0.009, respectively). And PPI, GO, KEGG, and GSEA also confirmed that IFI16 promoted MM progression by participating in tumor-related pathways. In conclusion, our study confirmed that IFI16 was a poor prognostic biomarker in MM.
基金：
Xinjiang Joint Fund of National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U1903117]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81500118]; Medical Scientific Research Foundation of Guangdong Province, China [A2019472]
第一作者单位：[1]Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[2]Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[3]Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[2]Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[3]Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumor Microenvironment, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China[4]Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, China[5]Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China
推荐引用方式(GB/T 7714)：
Huang Wenhui,Qian Tingting,Huang Zeyong,et al.Increased expression of IFI16 predicts adverse prognosis in multiple myeloma[J].PHARMACOGENOMICS JOURNAL.2021,21(4):520-532.doi:10.1038/s41397-021-00230-y.
APA：
Huang, Wenhui,Qian, Tingting,Huang, Zeyong,Liu, Yan,Cui, Longzhen...&Deng, Cong.(2021).Increased expression of IFI16 predicts adverse prognosis in multiple myeloma.PHARMACOGENOMICS JOURNAL,21,(4)
MLA：
Huang, Wenhui,et al."Increased expression of IFI16 predicts adverse prognosis in multiple myeloma".PHARMACOGENOMICS JOURNAL 21..4(2021):520-532
